
Richard E. Pratley
Articles
-
2 weeks ago |
healio.com | Michael Monostra |Richard E. Pratley
Key takeaways: Heart in Diabetes brings together leaders in the fields of cardiology, endocrinology, nephrology and more. Takeaways from this year’s meeting include medications for hypertension and hypercortisolism. PHILADELPHIA — Hypertension treatment and the role of cortisol in cardio-renal-metabolic health were among the featured topics from this year’s Heart in Diabetes CME Conference, according to Richard E. Pratley, MD. Pratley, the Samuel E.
-
Mar 26, 2025 |
healio.com | Michael Monostra |Richard Smith |Richard E. Pratley
Key takeaways: Diabetes Prevention Program investigators learned March 10 that government funding had been terminated. They said the program’s ongoing research may cease within weeks if funding is not restored. The future of the landmark Diabetes Prevention Program is in doubt after it lost federal funding for an ongoing long-term outcomes study and was forced to stop operations, according to the chair of the program.
-
Sep 27, 2024 |
radcliffecvrm.com | Helen M. Colhoun |John McMurray |Richard E. Pratley |Phyo T. Htoo
EASD 24 - We are joined by Dr Helen Coulhoun (University of Edinburgh, UK) to discuss the key findings of a prespecified analysis of the SELECT trial, which investigated the effectiveness of semaglutide in reducing major cardiac events in the presence of impaired kidney function in patients with overweight and obesity.
-
Sep 16, 2024 |
dom-pubs.onlinelibrary.wiley.com | Hertzel C. Gerstein |Stefano Del Prato |Renato D. Lopes |Richard E. Pratley
1 BACKGROUND/CONTEXT Glucagon-like-peptide-1 receptor agonists (GLP-1 RA) lower HbA1c by promoting insulin secretion in response to elevated glucose (the incretin effect).1, 2 They also slow gastric emptying; reduce appetite, weight, blood pressure, low-density lipoprotein (LDL) cholesterol and serious health outcomes3; and increase heart rate and pancreatic enzymes. The degree to which these nonglycaemic effects mediate their glycaemic effects remains unclear.
-
Sep 11, 2024 |
radcliffecardiology.com | Richard E. Pratley |Phyo T. Htoo |Julia Grapsa |Marta Sitges
Skip to main content Video Published: Views: 14 Likes: 0 Average (ratings) EASD 24 - Dr Phyo Htoo (Harvard Medical School, Boston, MA, US) joins us to discuss a study investigating the comparative effectiveness of empagliflozin and glucagon-like peptide-1 receptor agonists in combination as compared to either medication alone in patients with type 2 diabetes. Interview Questions:1. What was the reasoning for this study? 2.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →